Topical Maintenance Treatments in Chronic Dermatitis
References
- 1. Yan F, Zhang J, Li X, Mo X, Liu J, Ye S, et al. Therapeutic Effects of Chinese Herbal Formula (PTQX) on NC/Nga Mice with Atopic Dermatitis-Like Skin Lesions. Evid Based Complement Alternat Med. 2019;2019:1-13.10.1155/2019/1808419694831131949464
- 2. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816.10.1038/sj.jid.570062217096020
- 3. Rotaru M, Ionescu A, Rotaru BI, Iancu GM. Etiopathogenic and therapeutic considerations in atopic dermatitis. Acta Medica Transilvanica. 2019;24(2):34-38.
- 4. Mitchell AE. Bidirectional relationships between psychological health and dermatological conditions in children. Psychol Res Behav Manag. 2018;11:289-298.10.2147/PRBM.S117583607476230104911
- 5. Sadr Mohammadi R, Bidaki R, Mirdrikvand F, Mostafavi Yazdi SN, Yazdian Anari P. Peganum Harmala (Aspand) Intoxication; a Case Report. Emerg (Tehran). 2016;4(2):106-107.
- 6. Wollenberg A, Folster-Holst R, Saint Aroman M et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. JEADV. 2018;32 (Suppl. 1):1-15.10.1111/jdv.1484629533490
- 7. Kang NJ, Han SC, Yoon SH, Yoon JY, Maeng YH, Kang HK, et al. Cinnamomum camphora Leaves Alleviate Allergic Skin Inflammatory Responses In Vitro and In Vivo. Toxicol Res. 2019;35(3):279-285.10.5487/TR.2019.35.3.279662944631341557
- 8. Smeriglio A, Denaro M, Mastracci L, Grillo F, Cornara L, Shirooie S, et al. Safety and efficacy of hydroxytyrosol-based formulation on skin inflammation: in vitro evaluation on reconstructed human epidermis model. Daru. 2019;27(1):283-293.10.1007/s40199-019-00274-3659300131129807
- 9. Theoharides TC, Stewart JM, Tsilioni I. Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. Int J Immunopathol Pharmacol. 2017;30(2):146-151.10.1177/0394632017707610580679728480804
- 10. Lee JH, Lee YJ, Lee JY, Park YM. Topical Application of Eupatilin Ameliorates Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice. Ann Dermatol. 2017;29(1):61-68.10.5021/ad.2017.29.1.61531852928223748
- 11. Lee NR, Lee HJ, Yoon NY, Kim D, Jung M, Choi EH. Application of Topical Acids Improves Atopic Dermatitis in Murine Model by Enhancement of Skin Barrier Functions Regardless of the Origin of Acids. Ann Dermatol. 2016;28(6):690-696.10.5021/ad.2016.28.6.690512594927904267
- 12. Aries MF, Hernandez-Pigeon H, Vaissière C, Delga H, Caruana A, Lévêque M, et al. Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Clin Cosmet Investig Dermatol. 2016;9:421-434.10.2147/CCID.S113180510849327877060
- 13. Rashmi S, Nahid A, Tariq M. H. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. Life Sci. 2010;86(25-26):907-918.10.1016/j.lfs.2010.04.013314629420462508
- 14. Kowalska M, Mendrycka M, Zbikowska A, Kowalska D. Assessment of a stable cosmetic preparation based on enzymatic intersterified fat, proposed in the prevention of atopic dermatitis. Acta Pol Pharm. 2017;74(2):465-476.
- 15. Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis. JDD. 2015;14(12):1394-1399
- 16. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman N, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902-911.10.1111/bjd.1487127423107
- 17. Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. J Allergy Clin Immunol. 2019;144:1274-89.10.1016/j.jaci.2019.06.04731419544
- 18. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.10.1016/j.jaad.2016.05.04627417017
- 19. Gueniche A, Knaudt B, Schuck E et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159:1357-1363.10.1111/j.1365-2133.2008.08836.x18795916
- 20. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2019;1-12.10.1016/j.jaci.2019.08.04231629805
- 21. Awad N, Preuss CV. Halobetasol Cream. [Updated 2020 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from:https://www.ncbi.nlm.nih.gov/books/NBK544234/
- 22. Lee YW, Won CH, Jung K, Nam HJ, Choi G, Park YH, et al. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol. 2019;180(5):1030-1038.10.1111/bjd.17455685041930623408
- 23. Nakai K, Kubota Y, Soma GI, Kohchi C. The Effect of Lipopolysaccharide-containing Moisturizing Cream on Skin Care in Patients With Mild Atopic Dermatitis. In Vivo. 2019;33(1):109-114.10.21873/invivo.11446636405030587610
Language: English
Page range: 18 - 21
Submitted on: Jun 18, 2019
Accepted on: Aug 10, 2020
Published on: Oct 23, 2020
Published by: Lucian Blaga University of Sibiu
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2020 Maria Rotaru, Irina Mihaela Matran, Gabriela Mariana Iancu, published by Lucian Blaga University of Sibiu
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.